Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Venture Investing In Biotech Still Strong, Says E&Y Report

This article was originally published in The Pink Sheet Daily

Executive Summary

The 27th annual Beyond Borders report shows continued constraints to funding for biotechs, as they cut R&D and deal with a changing development landscape, but VC funding remains resilient.

You may also be interested in...



As Some New Listings Thrive, IPO Pipeline Burgeons

Encouraging results from some early 2013 offerings have led to four new filings in April. If the pattern holds, this year could be a better year for new listings than 2012.

Aastrom Stands Behind Its Decision To Shift Gears In Late Stages

The Michigan biotech is undergoing a complete restructuring as it cans its lead program and new management implements a different vision for the company.

Third Rock Continues To Attract Investors, Closes $516M Fund

The biotech venture firm continues to draw investors despite lacking a large number of exits for its portfolio companies. Its third fund brought in the largest investment yet for the firm.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS122308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel